Clinical Trial Search

Primary: Modified SANDE Questionnaire - Frequency, Change From Baseline — -22.00; -4.59 score on a scale — p=0.0197

Primary: Change in Patient-reported Symptoms Measured by the 8-point Lee Eye Subscale — 75.4; 63.2; 61.8; 56.3 units on a scale — p=0.01

Primary: Ocular Burning Sensation, Ocular Discharge, Ocular Redness, Ocular Itching, Foreign Body Sensation — 3.50; 2.23; 0.16; 0.26 units on a scale — p=0.0019

Primary: Change From Baseline (Visit 1) of Total Corneal Fluorescein Staining Score at 12 Weeks. — -4.2; -6.2; -2.1 units on a scale

Primary: Progression of Dry Eye Severity — 15; 12 patients with increased dry eye severity

Primary: Number of Patients That Develop Ocular GVHD While on Study in the Two Arms (Ocular Cyclosporine (Restasis) vs. Placebo) — 9; 8 participants — p=>0.99

Primary: Number of Participants Who Responded to Intense Pulsed Light (IPL) — 5; 2 participants

Primary: Overall Response Rate — 3; 6 eyes — p=0.375

Primary: The Clinical Efficacy of Topical Steroid and Topical Tacrolimus Therapies for the Treatment of Oral cGHVD. — 15; 3; 11; 2 participants

Primary: Number of Participants With an Overall Response at Week 28 — 20; 14 Participants — p=0.373

Primary: Maximum Tolerated Dose of Ofatumumab — 1000 mg

Primary: Proportion of Participants With Treatment Success — 33; 35; 33; 37 Participants — p=0.63

Primary: Feasibility of Enrolling Patients — 21 Participants

Primary: Number of Participants With the Ability to Successfully Taper Prednisone to a Dose Lower Dose. — 14 Participants

Primary: Incidence of Adverse Events — 8; 7 participants

Primary: Percentage of Participants With a Response as Assessed by the 273-point Oral Mucositis Rating Scale (OMRS) Who Received Topical Clobetasol 0.05% Oral Rinse for Oral…

Primary: Incidence of Adverse Events — 19; 18 participants

Primary: Ocular Symptoms and Signs Total Composite Score — 29.1; 4.7 units on a scale — p=0.002

Primary: Number of Participants Experiencing Treatment Success — 8 Participants

Primary: The Maximum Tolerated Dose and Toxicity Profile of an 8 Week Course of IL-2 in Patients With cGVHD and an Inadequate Response to Steroids. — 1 million IU/m2/day

Primary: Clinical Response of Patients With Refractory Chronic GVHD Based on the Working Group Report 2006. — 100; 78; 80 percentage of participants

Primary: Significant Clinical Response — 9; 10 participants

Primary: Overall Response at 6 Months — 0; 0; 7; 9 Participants

Primary: Overall Response (Complete Response + Partial Response + Other) — 7; 2; 0; 0 participants

Primary: Phase 1b: To Evaluate the Safety and Tolerability of Ibrutinib in Steroid Dependent/Refractory cGVHD. — 0 Participants

Primary: Day 56 Treatment Success — 57; 72; 43; 47 percentage of participants

Primary: Corticosteroid-Requiring Chronic Graft-Versus-Host Disease (cGVHD) Rate — 13.3; 35.2 percentage of participants — p=0.0008

Primary: Rate of Complete Response of cGVHD to Treatment. — 84 percentage of patients — p=<0.5

Primary: Percent Change in Absolute Range of Motion (ROM) From Baseline to 6 Months — 94; 35; 16; 21 Percent change from baseline

Primary: Percentage of Participants With Complete and Partial Responses in Skin and/or Joint — 49 percentage of participants